Activated aPKC-i/λ is upregulated in SMO inhibitor-resistant tumors, and targeting aPKC-i/λ suppresses GLI1 activation and the growth of SMO inhibitor-resistant BCC cell lines. This evidence concerns the gene SMO and skin basal cell carcinoma.